The recent findings brought the necessity of testing the mutational status of a series of genes which had been already identified as responsible for melanoma development and progression, such as BRAF, CKIT and PTEN (MEK and mTOR pathways): the consequent results are, in fact, essential to guide the assessment of the novel treatment protocols based on tailored targeted therapies. Here, PTEN is linked to melanoma.